BBX Logo Beta

ATAI Life Sciences (ATAI)

Crypto Stocks
ATAI Life Sciences
Thu, 4/30/2026, 09:02:29 PM
logo
ATAI Life Sciences
NASDAQ · $ATAI
Non-Strategic Token Holding
$4.155
+0.97%
Company Information

Atai Life Sciences NV is a clinical-stage biopharmaceutical company engaged in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company has developed BPL-003, a nasal formulation of mebufotenin in the form of a benzoate, which is currently in phase 2a and 2b clinical studies for the treatment of treatment-resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound that is a cognitive-enhancing neuromodulator, currently in phase 2b trials for the treatment of cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic, which is currently in phase 2a trials for the treatment of major depressive disorder. The company is also developing VLS-01, an oral mucosal formulation of N,N-dimethyltryptamine, which is currently in phase 2 clinical studies for the treatment of TRD; EMP-01, an oral R-3,4-methylenedioxy-N-methylamphetamine formulation, which is currently in phase 2 clinical studies for the treatment of social anxiety disorder; and EGX-A and EGX-B, non-psychedelic 5-HT2A receptor agonists, which are currently in preclinical studies for the treatment of TRD. Additionally, the company offers COMP360 for psilocybin therapy and GRX-917 for the treatment of anxiety disorders, depression, and various neurological diseases. ATAI Life Sciences NV was founded in 2018 and is headquartered in Berlin, Germany.

Coin Reserve Status
BTC
币种储备情况
As of July 2025, the company has not disclosed any information regarding its holdings of cryptocurrencies such as Bitcoin (BTC), Ethereum (ETH), and Solana (SOL) in any public documents. Its balance sheet primarily consists of cash, R&D pipeline, and equity investments.
Long press to scan QR code for more content
ATAI Life Sciences

ATAI Life Sciences

$ATAINASDAQ
Non-Strategic Token Holding
Buy Token

Company Information

Atai Life Sciences NV is a clinical-stage biopharmaceutical company engaged in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company has developed BPL-003, a nasal formulation of mebufotenin in the form of a benzoate, which is currently in phase 2a and 2b clinical studies for the treatment of treatment-resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound that is a cognitive-enhancing neuromodulator, currently in phase 2b trials for the treatment of cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic, which is currently in phase 2a trials for the treatment of major depressive disorder. The company is also developing VLS-01, an oral mucosal formulation of N,N-dimethyltryptamine, which is currently in phase 2 clinical studies for the treatment of TRD; EMP-01, an oral R-3,4-methylenedioxy-N-methylamphetamine formulation, which is currently in phase 2 clinical studies for the treatment of social anxiety disorder; and EGX-A and EGX-B, non-psychedelic 5-HT2A receptor agonists, which are currently in preclinical studies for the treatment of TRD. Additionally, the company offers COMP360 for psilocybin therapy and GRX-917 for the treatment of anxiety disorders, depression, and various neurological diseases. ATAI Life Sciences NV was founded in 2018 and is headquartered in Berlin, Germany.
CEO
Srinvas Rao
Founded
2025
Headquarters
Berlin, Germany
EXCHANGE
NASDAQ
H
Annual High
$5.50
View Related Announcements

Stock Chart

Business Model

Business Mode

ATAI Life Sciences is a clinical-stage biopharmaceutical company focused on developing and investing in therapies for depression, anxiety, addiction, and other mental health disorders. It has brought together multiple companies targeting the treatment of mental illnesses through incubation, acquisition, and investment, creating a platform that combines psychedelic compounds with digital therapeutics. The company provides resources such as R&D funding, expert team support, infrastructure, and advanced technology to these independently operating companies. Currently, no cryptocurrency-related business has been identified for this company.

Profit Model

The main profit expectation comes from the sales revenue after the successful launch of the developed medication for mental illness. Currently, the company is in the clinical research and development stage and has not yet launched any mature products for sale, so it has not achieved profitability, with financial data indicating a state of loss. There is no involvement in cryptocurrency-related profit models.

Profit Model Impact

The company's profit model aims to support high-risk drug development by diversifying collaborations to reduce the risk of individual projects. For example, the merger with Beckley Psytech has enhanced research and development capabilities in the field of treatment-resistant depression, while the collaboration with Otsuka has accelerated the commercialization process of PCN-101, a fast-acting antidepressant. The cryptocurrency business has no direct connection or impact in this model.

Impact on Cryptocurrencies

ATAI Life Sciences' business is not directly related to the cryptocurrency market, and therefore does not involve any impact on any cryptocurrency. Its stock price fluctuations are mainly influenced by clinical trial results, regulatory approval progress, and industry policies, rather than the dynamics of the cryptocurrency market.